What is Likarda?
Likarda operates at the intersection of biotechnology and material science, specializing in advanced drug delivery solutions. At the core of its value proposition is the proprietary Core-Shell Spherification (CSS) encapsulation platform, a sophisticated technology designed to enhance the efficacy of small molecules, biologics, and cell therapies. By providing customized hydrogel platforms and specialized cryopreservation solutions, the company enables research organizations to maintain the viability and function of living cells while ensuring precise control over drug release profiles.
The company serves as a vital infrastructure provider for the life sciences sector, addressing the inherent challenges of therapeutic stability and targeted delivery. Through its commitment to innovation, Likarda has transitioned from a specialized research entity into a scalable manufacturing partner, capable of meeting the rigorous demands of modern pharmaceutical development and clinical application.
How much funding has Likarda raised?
Likarda has raised a total of $4.1M across 2 funding rounds:
Series A
$4M
Debt
$144K
Series A (2017): $4M, investors not publicly disclosed
Debt (2021): $144K led by PPP
Key Investors in Likarda
Undisclosed Investor
An undisclosed investor participating in the funding round, providing essential capital to support Likarda's ongoing research and development initiatives.
PPP
Public-Private Partnership
Strategic Partner
An institutional backer focused on the long-term growth and scalability of advanced biotechnology platforms.
What's next for Likarda?
With the recent capital deployment, Likarda is positioned to accelerate its manufacturing capabilities and expand its footprint in the global drug delivery market. The strategic focus will likely center on scaling the production of its hydrogel delivery technologies to meet the increasing demand from enterprise-level pharmaceutical partners. Furthermore, the company is expected to deepen its research into cell therapy systems, aiming to refine its encapsulation techniques for broader clinical utility.
As Likarda moves into this next phase of growth, the emphasis will remain on operational excellence and the commercialization of its CSS platform. By strengthening its infrastructure and fostering collaborative partnerships, the firm is well-equipped to navigate the complexities of the biotech sector, ultimately driving improved treatment outcomes and setting new standards for therapeutic delivery.
